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Background:  Data on  atorvastatin  pretreatment  in  Asian  patients  with  acute  coronary  syndromes  (ACS)
undergoing  percutaneous  coronary  intervention  (PCI)  are  limited.  However,  there  have  been studies
in  other  populations  in Asia  which  demonstrated  that  statins  can  reduce  the  risk  of  periprocedural
myocardial  infarction  (MI).
Methods  and  results:  Statin-naïve  patients  with non-ST-segment-elevation  (NSTE)-ACS  scheduled  for
PCI were  randomized  to  usual  care  or atorvastatin  preloading  groups.  All  patients  received  usual  care
including  atorvastatin  40 mg/day.  The  atorvastatin  group  received  atorvastatin  80  mg 12 h and  40  mg 2 h
pre-PCI.  Of  499  patients  randomized,  247 were  assigned  to  atorvastatin  preloading.  Following  coronary
angiography,  335  patients  (163  atorvastatin)  received  PCI.  During  the  30  days  post-PCI,  major  adverse
cardiac  events  (death,  MI,  and  target  vessel  revascularization)  occurred  in 24  (15%)  atorvastatin  and  27
(16%) usual  care  patients  (p  = NS). Post  hoc  analyses  showed  that  at 8  h  post-PCI,  3.82%  of the  atorvastatin
group  and  7.22%  of  the  usual  care  group  had a post-procedural  creatine  kinase-myocardial  band  (CK-MB)
above 3 times  the  upper  limit  of  normal  (p  = 0.27)  and  at 24 h post-PCI,  the rate  was 7.64%  versus 9.47%
(p =  1.0).  Safety  proﬁle  suggests  that  high-dose  atorvastatin  (40 mg)  for  up to 1 month,  in  conjunction
with usual  care,  is  relatively  safe  and  well  tolerated.
Conclusions:  This  study  of  statin-naïve  Korean  and  Chinese  patients  with  NSTE-ACS  who  received  addi-
tional  atorvastatin  loading  doses  of  80  mg  at 12 h, and  40 mg  at 2 h, pre-PCI  did  not  ﬁnd  a  beneﬁcial
effect compared  with  usual  post-PCI  atorvastatin  40 mg/day  treatment.  Atorvastatin  was  found  to be
well  tolerated  in  Asian  patients  with  NSTE-ACS  undergoing  PCI.  Results  of  the  current  study  merit  fur-
ther  investigation  of  the  early  use of  statins  in  patients  with  NSTE-ACS  to  delineate  patient  subgroups
is  the
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Recently, the potential of statin therapy to improve cardiovas-
ular outcomes in acute coronary syndromes (ACS) or in association
ith percutaneous coronary interventions (PCI) has attracted
ncreasing interest.
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The earliest randomized trials of statin therapy in patients
undergoing PCI—the Atorvastatin for Reduction of MYocardial
Damage during Angioplasty (ARMYDA) studies—demonstrated
beneﬁcial effects of statin pretreatment on periprocedural major
adverse cardiac events (MACE) in a range of acute patient groups
[1–5]. Other trials have followed, also with largely positive results
[6–11]. In a meta-analysis including 2088 statin-naïve PCI patients,
periprocedural myocardial infarction (MI) occurred in signiﬁcantly
fewer patients after statin pretreatment than control [7]. Another
meta-analysis comprising 4805 patients from 21 randomized,
controlled trials demonstrated that pre-procedural statin use sig-
niﬁcantly reduced post-procedural MI  after PCI and other surgery
[8].
vier Ltd. All rights reserved.
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While most studies have involved Western populations, some
ata in Asian patients have emerged [12–16]. In a Korean trial
nvolving 445 ACS patients receiving PCI, MACE occurrence was
0.5% in the control group versus 9.8% in those who received
re-PCI rosuvastatin 40 mg  [14]. Another study in 80 Chinese
atients with non-ST-segment-elevation (NSTE)-ACS who  received
tent implantation established that high-dose, short-term pre-
CI atorvastatin was well tolerated with beneﬁcial myocardial
ffects positively correlated with dose and frequency of atorvas-
atin administration [13].
Here, we report the results of the Asian Lipitor Pretreatment in
CS (ALPACS) study, which assessed the effect of pretreatment with
torvastatin on cardiovascular events in statin-naïve patients with
STE-ACS scheduled for PCI in China and the Republic of Korea.
ethods
tudy design
The protocol of ALPACS (NCT00728988, www.clinicaltrials.gov)
as been described in detail previously [17]. This prospective, open-
abel study included statin-naïve Asian patients aged ≥18 years
ith NSTE-ACS (deﬁned as unstable angina or NSTE-acute MI  with
oronary angiography to be undertaken within 72 h of the onset of
ymptoms) and low-density lipoprotein cholesterol (LDL-C) levels
2.07 mmol/L (80 mg/dL) at screening.
Key exclusion criteria included ST-segment elevation acute MI,
STE-ACS with predeﬁned features warranting emergency coro-
ary angiography, left ventricular ejection fraction (LVEF) <30%, and
revious or current statin treatment. Key prohibited medications
ere antilipidemic medication and cytochrome P450 inhibitors.
ee Appendix A for all exclusion criteria and prohibited medica-
ions.
The ALPACS study followed the Declaration of Helsinki and was
pproved by the ethics committee or institutional review board
t each investigation site. Written informed consent was obtained
rom all patients.
Patients were randomized to either atorvastatin treatment
atorvastatin loading doses pre-PCI plus usual care) or usual care
usual care only). Screening occurred within 72 h prior to PCI.
nrolled patients were assessed at 12 and 2 h pre-PCI, 8 and 24 h
ost-PCI, and at end-of-study (30 days post-PCI). Assessments
ncluded physical examination; vital signs; electrocardiogram
ECG); and blood sampling for laboratory tests, including hemato-
ogy, lipids, biochemistry, C-reactive protein (CRP), urinalysis, and
ardiac biomarkers (troponin I, creatine kinase-myocardial band
CK-MB], and myoglobin).
Usual care treatments were in accordance with the Ameri-
an College of Cardiology/American Heart Association (ACC/AHA)
007 Guidelines for the Management of Patients with Unsta-
le Angina/NSTE-MI [18]. Aspirin-naïve patients received aspirin
ccording to local practice, 200–300 mg  loading dose pre-PCI, and
00–200 mg/day thereafter. Patients taking aspirin at screening
ontinued with their regimen. Clopidogrel 300 mg  loading dose was
dministered at least 3 h pre-PCI and 75 mg/day thereafter. Dur-
ng hospitalization, patients also received subcutaneous heparin,
noxaparin (1 mg/kg every 12 h pre-PCI, every 12 h thereafter, or for
t least 48 h post-PCI; or every 24 h if estimated creatinine clearance
as <30 mL/min), or dalteparin [120 IU/kg (maximum 10,000 IU)
very 12 h pre-PCI, every 12 h thereafter, or for a minimum of 48 h
ost-PCI]. Usual care also included atorvastatin 40 mg/day after PCI
or 30 days. Patients in the atorvastatin group received all usual
are treatments, plus atorvastatin loading doses of 80 mg  at 12 h
nd 40 mg  at 2 h pre-PCI.
Safety of atorvastatin was evaluated by the incidence, sever-
ty, and relationship to treatment of adverse events (AEs)logy 63 (2014) 335–343
including clinically signiﬁcant changes in vital signs, ECG, and phys-
ical examination ﬁndings, also changes in laboratory parameters.
Treatment-emergent AEs (TEAEs) of all-causality reported for ≥5%
of patients in either treatment group were summarized.
Patient analysis sets and endpoints
Efﬁcacy analysis was  performed on the full analysis set (FAS:
all patients who  received ≥1 dose of study treatment and PCI) and
per protocol (PP) analysis set. The FAS was  the primary analysis
set and was  used for both primary and secondary efﬁcacy analy-
ses. The PP analysis set was used for the primary efﬁcacy analysis
only and included all patients who: (1) received ≥1 dose of study
treatment; (2) were treated for ≥14 days, or discontinued before
this time due to treatment failure; (3) were 80–120% compliant
with the randomized treatment; (4) underwent PCI within 72 h of
the onset of symptoms and 24 h of the ﬁrst dose of atorvastatin;
and (5) did not violate any inclusion or exclusion criteria that could
affect the efﬁcacy results.
The primary endpoint was  the incidence of MACE (death, MI, and
target vessel revascularization). By using the universal deﬁnition of
MI [19], MI  was  deﬁned biochemically as spontaneous [increased
troponin exceeding 99th percentile of the upper reference limit
(URL)] and PCI-associated (increased cardiac biomarker of more
than 3 × 99th percentile of URL). Secondary endpoints included the
incidence of MACE at 8 and 24 h post-PCI; the proportion of patients
with any elevated biomarkers of myocardial injury (troponin I, CK-
MB,  and myoglobin) above the upper limit of normal (ULN) at 8 h,
24 h, and 30 days post-PCI; the change in CRP at these time points;
and the safety and tolerability proﬁle of atorvastatin in the presence
of underlying usual care in this population.
Statistical methods
For each group, enrollment of 251 patients was  planned to allow
for approximately 158 evaluable (i.e. treated and received PCI)
patients. The study was powered with 90% chance of detecting a
difference in MACE incidence of 17% versus 5% between treatment
groups within 30 days post-PCI. The difference in MACE (and its
three components) incidence within 30 days post-PCI between the
treatment groups was  presented with a p-value and 95% conﬁdence
interval (CI) calculated by a 5% two-sided continuity-corrected chi-
squared test. Fisher’s exact test was  used whenever the expected
frequency of events was  <5.
Unadjusted odds ratio (OR) and 95% CI for MACE (and its three
components) at 30 days post-PCI were calculated by a logistic
regression model using treatment group as the only covariate with
the usual care group as the reference; adjusted OR and 95% CI were
calculated by including treatment group and the following poten-
tial confounding covariates: age, gender, country, NSTE-MI, LVEF
≥40%, and use of beta-blockers, angiotensin-converting enzyme
(ACE) inhibitors, angiotensin receptor blockers, calcium channel
antagonists, or diuretics.
MACE- and MI-free comparison up to 30 days post-PCI between
treatment groups was  analyzed using Kaplan–Meier method with
a log-rank test.
For secondary efﬁcacy analyses, incidence rates of MACE within
8 and 24 h post-PCI and the proportions of patients with any ele-
vated biomarkers of myocardial injury above the ULN from baseline
at 8 h, 24 h, and 30 days post-PCI were compared by treatment
group and visit. The difference in the proportions was analyzed
using the same calculation method used for MACE analysis.During the trial, the high sensitivity-CRP reagents used for 207
samples were found unstable, leading to an overall 20% positive bias
for affected samples. To evaluate the impact of the affected sam-
ples, a sensitivity analysis was performed for the following sample
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:
1 had AE†
1 did not meet 
entrance criteria
1 withdrawn†
79 other‡
Screening 
 
Assigned treatment
•
pre-angiography and 
pre-angiography plus 
usual care*
• Usual care* 
Coronary angiography
PCI
Primary endpoint:
MACE occurrence 
at 30 days post-PC I
screened
6 excluded
Usual care group
   
154 (62.3%) completed
FAS: 163 paents  (66.0%)
PP: 90 paents (36.4%)
164 (65.1%) completed
2 from each group  
excluded 
1 had AE†
1 violated protocol 
1 did not meet 
entrance criteria
3 withdrawn† 
72 other‡
:
2 had AE†
1 died 
3 did not meet 
entrance criteria
1 withdrawn†
2 other
:
1 had AE†
1 died 
1 did not meet 
entrance criteria
3 withdrawn†
2 other
30 days
Fig. 1. Patient disposition. *Usual care was supplied to all patients in accordance
with the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable
Angina/Non-ST-Elevation Myocardial Infarction [18]. Management included treat-
ment with aspirin, clopidogrel, subcutaneous heparin, and atorvastatin 40 mg daily
post-PCI for 30 days. See Method section for more details. †Not related to study treat-
ment. ‡This number included the patients who were considered not to require PCI.
ACC/AHA, American College of Cardiology/American Heart Association; AEs, adverse
events; FAS, full analysis set; MACE, major adverse cardiac events; NSTE-ACS, non-
ST elevation acute coronary syndromes; PCI, percutaneous coronary intervention;Y. Jang et al. / Journal of C
roups: all (including the affected) samples with appropriate data
orrection, unaffected samples, and affected samples with data cor-
ection. Percentage changes in CRP from baseline at 8 h, 24 h, and 30
ays post-PCI were analyzed in each sample group and compared
y treatment groups using analysis of variance (ANOVA).
ost hoc analyses
A series of post hoc analyses were conducted. To evaluate
ardiovascular risk between the randomized group and the FAS,
ramingham risk score was calculated based on age, levels of LDL-
 and high-density lipoprotein cholesterol, systolic and diastolic
lood pressure, and diabetes mellitus status. LDL-C between treat-
ent groups at different visits [12 h pre-PCI (i.e. baseline); 8 h, 24 h,
nd 30 days post-PCI] was analyzed. Various subset analyses were
erformed by site, country, and demographic and disease status, in
hich patients were evaluated by low LVEF (≤40%), usage of beta-
locker and diuretics; and the occurrence of all three was used as
 marker for more severe illness. The consistency in the investiga-
or’s adjudication of MI/MACE and the deﬁnition of MI  by troponin
 was checked. Proportions of patients with a CK-MB measurement
2 or 3 × ULN from baseline at 8 h, 24 h, and 30 days post-PCI were
ompared by treatment group and visit. The elevation of cardiac
iomarkers was also analyzed in patients with unstable angina.
esults
atient population
Of the 505 patients screened, 499 met  the inclusion criteria, with
47 assigned to the atorvastatin group and 252 to the usual care
roup. Patient disposition is summarized in Fig. 1. Baseline charac-
eristics were similar between treatment groups (Table 1). In the
AS, the mean age was 60 ± 10 years and 72% of patients were male;
STE-MI occurred in 41% of patients.
ardiovascular events and biomarker results
Analysis of the FAS (Table 2) showed that during the 30 days
ost-PCI, MACE occurred in 24/163 (14.7%) atorvastatin patients
nd 27/172 (15.7%) usual care patients, with no statistically sig-
iﬁcant difference between the treatment groups (OR 0.93, 95% CI
.51–1.68, p = 0.80). There was also no statistically signiﬁcant dif-
erence between the treatment groups in MACE-free Kaplan–Meier
urves (Fig. 2). The results were similar in the PP analysis set (Table 2
nd Fig. 2). As a secondary endpoint, the incidence of MACE at 8
nd 24 h post-PCI showed no statistically signiﬁcant difference by
reatment.
For the CRP analysis, there was no statistically signiﬁcant dif-
erence between treatment groups in: (1) all samples, (2) samples
naffected by the unstable reagents, or (3) the affected samples
Fig. 3).
afety results
The proportion of patients with all-causality TEAEs was sim-
lar in the atorvastatin and usual care groups [116/245 (47.3%)
s. 119/250 (47.6%) patients]; while the proportion of patients
eporting treatment-related TEAEs was slightly higher in the
torvastatin group [40/245 (16.3%) vs. 31/250 (12.4%) patients].
imilar proportions of patients in the atorvastatin and usual care
roups [8/245 (3.3%) vs. 9/250 (3.6%)] reported all-causality severe
EAE. Although no patient had a dose reduction or temporary
iscontinuation due to TEAE, 3/245 (1.2%) atorvastatin patients
nd 2/250 (0.8%) usual care patients discontinued the study due toPP,  per protocol.
all-causality AEs. All-causality TEAEs that were reported for ≥5%
of patients in either treatment group are listed in Table 3.
Myalgia developed in 3/250 (1.2%) usual care patients. Two of
the three incidences of myalgia were considered treatment-related
by the investigators. Severity assessment showed that one (0.4%)
patient had mild myalgia and one (0.4%) patient had moderate
myalgia. No patients in the atorvastatin group had myalgia.
Two  deaths (death and angina unstable, respectively) occurred
in the atorvastatin group. Another patient who received usual care
died 11 days after the last visit from acute MI,  ischemia, acute renal
failure, and rhabdomyolysis.
Overall, single elevations in liver function tests (>3 × ULN) were
reported in <5% of patients in ALPACS. The most common laboratory
test TEAE (all-causality and treatment-related) in both treatment
groups was  alanine transaminase (ALT) increase. As an all-causality
TEAE, ALT increased in 4/245 (1.6%) and 9/250 (3.6%) patients in
the atorvastatin and the usual care groups; as a treatment-related
TEAE, ALT increased in 4/245 (1.6%) and 7/250 (2.8%) patients in
each group. There were no notable median changes from baseline
to last observation (samples taken at the last visit) in any laboratory
parameter in either treatment group, except that LDL-C decreased
by 1.50 and 1.24 mmol/L (58 and 48 mg/dL) and CK decreased by 12
and 18 U/L in the atorvastatin and usual care groups, respectively.
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Table 1
Baseline characteristics of the full analysis set.
Characteristic Usual carea with
pre-PCI atorvastatin
loading (N = 163)
Usual carea
only (N = 172)
p-Value
Age, years 60 ± 10 61 ± 9.2 0.7056
Male gender 116 (71.2) 126 (73.3) 0.7604
NSTE-MI 64 (39.3) 72 (41.9) 0.7096
Smoking status NA NA
Diabetes mellitus 32 (19.6) 38 (22.1) 0.6750
Hypertension 95 (58.3) 108 (62.8) 0.4640
Dyslipidemia 27 (16.6) 37 (21.5) 0.3114
Prior myocardial
infarction
2 (1.2) 5 (2.9) 0.4494
Prior stroke 6 (3.7) 18 (10.5) 0.0282
Peripheral artery
disease
NA NA
Severity of coronary
artery disease
NA NA
LVEF ≤40% 3 (1.8) 5 (2.9) 0.7239
LVEF ≥30% and <40% 2 (1.2) 4 (2.4) 0.6852
Creatinine 0.94 ± 0.24 0.97 ± 0.25 0.3346
Creatinine clearance NA NA
Concomitant medications
Aspirin 163 (100.0) 172 (100.0) –
Clopidogrel 90 (55.2) 88 (51.2) 0.5265
Beta blockers 123 (75.5) 120 (69.8) 0.2963
ACE inhibitors 74 (45.5) 87 (50.6) 0.4012
Glycoprotein IIb/IIIa
inhibitors
31 (19.0) 39 (22.7) 0.4913
Values are n (%) or mean ± SD.
ACC/AHA, American College of Cardiology/American Heart Association; ACE,
angiotensin-converting enzyme; LVEF, left ventricular ejection fraction; NA, not
available; NSTE-MI, non-ST-segment elevation myocardial infarction; PCI, percu-
taneous coronary intervention; SD, standard deviation.
a Usual care was  supplied to all patients in accordance with the ACC/AHA 2007
Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation
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Fig. 2. Kaplan–Meier curves of MACE-free survival up to day 30. (A) Full analysis set;
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syocardial Infarction [18]. Management included treatment with aspirin, clopido-
rel, subcutaneous heparin, and atorvastatin 40 mg  daily post-PCI for 30 days. See
ethod section for more details.
ost hoc analysis
Post hoc analysis showed that for all randomized patients and
hose included in the FAS, Framingham coronary heart disease
CHD) risk score and 10-year CHD risk were similar in both treat-
ent groups. LDL-C reductions (baseline to end-of-study) were
ppropriate for the dose of atorvastatin used (Supplement Table
), and no signiﬁcant difference was detected for site, country,
emographic, and disease status in any of the subsets.
able 2
he incidence of major adverse cardiac events (MACE).
Incidencea
Usual careb with pre-PCI
atorvastatin loading
Usual c
Full analysis set N = 163 N = 172
Total MACE, n (%) 24 (14.7) 27 (15.7
Death, n (%) 1 (0.6) 1 (0.6) 
MI,  n (%) 23 (14.1) 26 (15.1
Per protocol analysis set N = 90 N = 114
Total MACE, n (%) 10 (11.1) 14 (12.3
Death, n (%) 0 0
MI,  n (%) 10 (11.1) 14 (12.3
CC/AHA, American College of Cardiology/American Heart Association; CI, conﬁdence in
f  patients in the evaluable population; n, number of patients who experienced the event
a Incidences of MACE after 33 days post-PCI are excluded.
b Usual care was  supplied to all patients in accordance with the ACC/AHA 2007 Gui
yocardial Infarction [18]. Management included treatment with aspirin, clopidogrel, su
ection  for more details.
c Difference of incidence = usual care − atorvastatin.
§ p-Value is from the continuity-adjusted Chi-square test.
|| p-Value is from the Fisher’s exact test.(B)  per protocol analysis set. MACE, major adverse cardiac events; PCI, percutaneous
coronary intervention.
Supplementary material related to this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jjcc.2013.09.012.Analysis of CK-MB showed that there was  a tendency, although
not statistically signiﬁcant, for the percentage of patients with an
increase in CK-MB (>2 or >3 × ULN) to be lower in the atorvastatin
Treatment difference (%)
areb only Difference of incidencec (95% CI) p-Value
) 1.0 (−7.3, 9.3) 0.9237§
0.0 (−10.7, 10.7) 1.0000||
) 1.0 (−7.2, 9.2) 0.9158§
) 1.2 (−8.7, 11.0) 0.9692§
) 1.2 (−8.7, 11.0) 0.9692§
terval; MACE, major adverse cardiac events; MI,  myocardial infarction; N, number
; PCI, percutaneous coronary intervention.
delines for the Management of Patients with Unstable Angina/Non-ST-Elevation
bcutaneous heparin, and atorvastatin 40 mg daily post-PCI for 30 days. See Method
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Fig. 3. Mean change from baseline in CRP by visit in the full analysis set. (A) All samples; (B)
coronary intervention.
Table 3
Treatment-emergent adverse events (all-causality) reported for ≥5% of patients in
either treatment group.
Most frequent AEs by
Medical Dictionary for
Regulatory Activities
(v13.0)
Usual carea with
pre-PCI atorvastatin
N = 245
Usual carea only
N  = 250
Cardiac disorders 31 (12.7) 28 (11.2)
Gastrointestinal disorders 26 (10.6) 25 (10.0)
General disorders and
administration site
conditions
36 (14.7) 36 (14.4)
Investigations 10 (4.1) 21 (8.4)
Musculoskeletal and
connective tissue
disorders
18 (7.3) 16 (6.4)
Nervous system disorders 35 (14.3) 27 (10.8)
Vascular disorders 7 (2.9) 14 (5.6)
Values are n (%).
All data collected since the ﬁrst dose of study treatment are included.
N, number of patients in the evaluable population (patients were only counted once
per treatment for each row).
ACC/AHA, American College of Cardiology/American Heart Association; AE, adverse
event; PCI, percutaneous coronary intervention.
a Usual care was  supplied to all patients in accordance with the ACC/AHA 2007
Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation
Myocardial Infarction [18]. Management included treatment with aspirin, clopido-
grel, subcutaneous heparin, and atorvastatin 40 mg  daily post-PCI for 30 days. See
Method section for more details. unaffected samples; (C) affected samples. CRP, C-reactive protein; PCI, percutaneous
group than in the usual care controls. The difference in trend
between the two groups was evident at 8 h post-PCI (Fig. 4).
It was also found that the troponin I value and the investigators’
assessment of MI  were inconsistent. For instance, at 8 h post-PCI,
of the 48 patients in the atorvastatin group who had an elevation
of troponin I with ≥3 × 99th percentile URL, 38 (79.2%) patients
were assessed by the investigators as not having MI.  Similar rates
of inconsistency were found in both groups at 8 and 24 h post-PCI
(both p > 0.6). The analyses on cardiac biomarkers in patients with
unstable angina showed no signiﬁcant differences between the two
treatment arms.
Discussion
The present study was  carried out in a statin-naïve Asian ACS
population undergoing PCI, comparing with patients in the control
group who  received usual care that included post-PCI atorvas-
tatin treatment of 40 mg/day. There was no signiﬁcant reduction
in MACE in patients in the treatment arm who  received additional
loading doses of atorvastatin 80 mg  at 12 h pre-PCI and 40 mg  at
2 h pre-PCI. There were also no signiﬁcant differences between
treatment groups in the proportions of patients who had ele-
vated levels of troponin I, CK-MB, and myoglobin post-PCI, or in
CRP change from baseline. These results are unexpected as the
current study design resembles closely that of ARMYDA-ACS [3].
Since publication of ARMYDA-ACS, there have been meta-analyses
of statin treatment in the periprocedural reduction of adverse
cardiovascular events in ACS (including Asian populations), which
340 Y. Jang et al. / Journal of Cardio
Fig. 4. Patients with elevated CK-MB >2× or >3 × ULN by visit in the full analysis
set.  (A) CK-MB elevations >2 × ULN; (B) CK-MB elevations >3 × ULN. N, number of
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ratients with baseline and at least one post-baseline response; n, number of patients
ith elevated CK-MB. CK-MB, creatine kinase-myocardial band; PCI, percutaneous
oronary intervention; ULN, upper limit of normal.
upport the beneﬁcial effects of statins initiated before PCI in ACS
atients.
Contrary to this body of evidence, there has been one study that
id not demonstrate reductions in cardiovascular outcomes with
torvastatin pretreatment before PCI [20]. This study evaluated
atients with stable angina who were treated with atorvastatin
0 mg/day for 2 days pre-PCI; however, it excluded ACS patients.
he authors attributed the results to a possible greater beneﬁt of
tatins in ACS (vs. stable angina), a small sample size (n = 100/arm),
nd low incidence of the primary endpoint (periprocedural MI  or
ll-cause death) [20].
To identify confounding factors that could have led to the lack
f statin beneﬁt in ALPACS, post hoc analyses were performed, the
esults of which found no signiﬁcant confounding effects associ-
ted with the atorvastatin supplies used, investigator sites, country,
emographic, and disease status, or the cardiovascular risk of dif-
erent patient groups; nor with the investigators’ assessment of
ACE among patients with different treatments.
Statins have been proven to be beneﬁcial and guidelines rec-
mmend the use of statins in patients with ACS. In the PRavastatin
r atorVastatin Evaluation and Infection Therapy – Thrombolysisn MI  (PROVE IT-TIMI) 22 trial, the risk of the primary endpoint
death, MI,  unstable angina requiring rehospitalization, stroke,
r revascularization occurring ≥30 days after initial event) was
educed by 16% after intensive lipid-lowering with atorvastatinlogy 63 (2014) 335–343
80 mg  compared with moderate lipid-lowering from pravastatin
40 mg  (22.4% vs. 26.3%, p = 0.005) [21]. A PROVE IT-TIMI 22 sub-
study further demonstrated that compared with moderate-dose
statin therapy, for patients with ACS who undergo PCI, high-dose
statin therapy signiﬁcantly reduces MACE [22]. Similarly, in
the Myocardial Ischemia Reduction with Aggressive Cholesterol
Lowering (MIRACL) study, compared with placebo, atorvastatin
treatment signiﬁcantly reduced the risk of the primary com-
bined endpoint (death, nonfatal acute MI,  cardiac arrest with
resuscitation, or recurrent symptomatic myocardial ischemia with
objective evidence and requiring emergency rehospitalization)
[23].
More recently, a body of evidence has been emerging that sup-
ports the use of pre-PCI statins in ACS patients [1–5,13,14]. In a
meta-analysis using individual patient data from 13 randomized
studies, Patti et al. demonstrated that for the 3341 patients under-
going PCI, pre-PCI high-dose statin therapy signiﬁcantly reduced
periprocedural MI  and 30-day post-PCI AEs [24]. Similar results
were reported by Ko et al. in an observational study including
12,980 patients aged >65 years with stable coronary artery dis-
ease who  underwent PCI; at 90 days post-PCI, the incidence of
death and ACS was 5.6% in the pre-procedural statin group and 7.4%
in the no-pretreatment group (p = 0.005) [25]. Consequently, the
2011 ACC Foundation/AHA/Society for Cardiovascular Angiography
and Interventions Guideline for PCI recommended pre-PCI admin-
istration of high-dose statin for risk reduction of periprocedural MI
[26]. Similarly, the European Society of Cardiology (ESC)/European
Atherosclerosis Society Guidelines for the Management of Dys-
lipidaemias acknowledged the beneﬁcial effects of atorvastatin
short-term pre-PCI treatment in statin-naïve patients with both
stable angina and ACS [27]; a high-dose statin preloading pre-PCI
has been suggested for patients taking statins to reduce the risk of
periprocedural MI  [27].
The design of ALPACS resembles most closely that of the
ARMYDA-ACS, in which pretreatment with atorvastatin 80 mg 12 h
and 40 mg  2 h before PCI was shown to reduce 30-day MACE inci-
dence by 88% [3]. The fact that ALPACS did not replicate this effect
may  reﬂect differences in baseline characteristics, diagnostic deﬁ-
nitions, or procedures between the two studies. ALPACS followed
the 2007 guidelines for MI  diagnosis and management issued by the
joint ESC/AHA/World Heart Federation task force [19] and deﬁned
PCI-associated MI  as troponin I elevation ≥3 × 99th percentile URL
for normal baseline troponin, and for abnormal baseline troponin
as troponin I elevation ≥3 × 99th percentile URL plus ECG/imaging
evidence if troponin levels were either stable or falling. Recent
evidence has suggested that troponin could be oversensitive as a
marker for periprocedural MI  [28]. One of the latest publications
demonstrated that among the 26 of 32 (81%) patients receiving
multivessel intervention who  had elevated troponin, only 5 had
evident myocardial necrosis [29]. This oversensitivity of troponin
as a marker for PCI-related MI  was also found in the post hoc anal-
ysis of ALPACS: a high inconsistency between elevated troponin
I value and the investigators’ assessment of MI  occurred in both
groups and at all time points. Based on the Third Universal Deﬁni-
tion of MI  [30], which deﬁned PCI-related MI  as >5 × 99th percentile
URL combined with clinical signs or imaging abnormalities, a post
hoc analysis was  performed on post-PCI troponin changes. Given
that documentation of peri-PCI symptoms and imaging were not
performed per protocol for ALPACS (unless an adverse event was
reported), an analysis using the latest deﬁnition of PCI-related MI
was not possible. Results of this post hoc analysis, however, showed
no differences between the two treatment arms of ALPACS.Further post hoc investigations in biomarkers of ALPACS con-
ﬁrmed the lipid-lowering effects of atorvastatin in this Asian
patient population; moreover, it was revealed that percentages of
patients with CK-MB increases (>2 or >3 × ULN) in ALPACS were
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umerically lower in the atorvastatin group than in usual care con-
rols.
It has been acknowledged that lesion severity (e.g. multives-
el disease) of the patients and the intervention (e.g. receiving
ultivessel intervention, usage of drug-eluting stents) may  con-
ribute to outcomes. In ARMYDA-ACS, 34% of atorvastatin patients
nd 46% of placebo patients had multivessel disease, but not all
atients with multivessel disease received multivessel interven-
ions (atorvastatin, 20%; placebo, 29%) [3]. Drug-eluting stents were
sed in 64% of atorvastatin patients and 55% of placebo patients
n ARMYDA-ACS [3]. In China and the Republic of Korea, where
LPACS was performed, drug-eluting stents were the predominant
evices used. Whether the types of coronary artery lesion were
mbalanced between treatment groups of ALPACS cannot be fully
lucidated, as this information was not captured. However, review
f studies of statin pretreatment in PCI with anatomically docu-
ented coronary artery lesion suggests that when sample size was
tatistically calculated (as in ALPACS), differences in coronary artery
natomy within the overall sample have been evenly distributed
cross treatment arms – and did not contribute signiﬁcantly to the
verall treatment outcomes.
Some bias may  exist because ALPACS was open-label and inves-
igators were aware of the treatment allocation. However, the use
f aspirin, heparin, and clopidogrel was strictly controlled between
rms.
Other possible confounding variables (age, gender, LVEF, ACS
iagnostic category, and usage of beta-blockers, calcium channel
lockers, or diuretics) were evaluated. No apparent imbalances
ere detected between the two arms at baseline. Logistic
egression analysis adjusted by these factors did not alter the
esults. When compared with ARMYDA-ACS, ALPACS had greater
eta-blocker use (73% vs. 29%) and less ACE inhibitor use (48% vs.
7%). However, there was no signiﬁcant imbalance in history of
ypertension (61% vs. 74%) and diabetes (21% vs. 31%), with the
revalence of these conditions being a little lower in ALPACS. In
oth ARMYDA-ACS and ALPACS, 100% of patients received clopido-
rel. In ARMYDA-ACS, the periprocedural MI  rate in the placebo arm
as 15% [3], which was considerably higher than that of the ator-
astatin arm (5%), but also lower than that of the general population
f patients with ACS/stable angina (≥18%; personal communication
ith investigators of ARMYDA-ACS). This lower-than-normal rate
ay have been the result of the 600-mg loading dose of clopidogrel
sed in all ARMYDA-ACS patients to provide additional cardiopro-
ection.
The overall sample size is unlikely to be a factor in the results of
LPACS, since it had twice the sample size of ARMYDA-ACS and met
he sample size requirement at study end (n = 318). For both studies,
andomization occurred before the diagnostic angiogram, follow-
ng which, the investigator may  determine that the patient did not
equire PCI. This occurred in 10% (20/191) in ARMYDA-ACS and
3% (164/499) in ALPACS. This difference in the non-progression
o PCI may  underpin the possibility that the patients who under-
ent PCI in ALPACS might be at lower cardiovascular risk than
n ARMYDA-ACS. If subject selection were to be biased against
igh-risk patients, and if this were considered in light of biomarker
oversensitivity’ in MI  detection, it is conceivable that these factors
ould lead to an apparent lack of beneﬁt with atorvastatin.
While an effect from racial differences on our results cannot be
ully discounted, usually the cardiovascular risk in Asian patients is
he primary confounder rather than race per se. Indeed, data from
ther recently published Asian studies have supported the bene-
ts of statin pretreatment. In another atorvastatin study, pre-PCI
oading with the statin signiﬁcantly reduced short-term MACE in
hinese patients with NSTE-ACS who received stent implanta-
ion, although the patient numbers were small (n = 20/arm) [13].
n a Korean study of rosuvastatin, high-dose loading before PCIlogy 63 (2014) 335–343 341
signiﬁcantly improved 12-month clinical outcomes in patients with
ACS who  underwent an early invasive strategy [14].
The safety proﬁle of atorvastatin in Asian patients in the present
study suggests that high-dose atorvastatin (40 mg)  for up to 1
month, in conjunction with usual care, is relatively safe and well
tolerated. The safety proﬁle of high-dose atorvastatin in predomi-
nantly Caucasian patient populations is also supported by landmark
clinical trials such as the Treating to New Targets study [31] and
PROVE IT-TIMI 22 [21]. The favorable safety of atorvastatin in this
population of Chinese and Korean patients is also in agreement
with some of the key studies of atorvastatin that were previously
undertaken in East Asian patients [32–35].
Although ALPACS did not demonstrate a beneﬁcial effect of
atorvastatin preloading in PCI in the Korean and Chinese patients
with NSTE-ACS who were studied, there have been similar stud-
ies in other populations in Asia which demonstrated that statins
can reduce the risk of periprocedural MI.  Supporting this hypoth-
esis is the lower incidence of increased CK-MB with atorvastatin
pre-treatment than that in usual care controls as observed in this
study. In ALPACS, atorvastatin was found to be well tolerated in
Asian patients with NSTE-ACS undergoing PCI.
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Appendix A.
Exclusion criteria
• Female patients who were pregnant, lactating, planning a
pregnancy during the course of the study, or who  were of
child-bearing potential and not using an acceptable method of
birth control
• ST-segment elevation acute MI
• NSTE-ACS with ≥6 of the following 7 risk features warranting
emergency coronary angiography:
- Aged ≥65 years
- ≥3 risk factors for coronary artery disease
- Prior coronary stenosis of ≥50%
- ST-segment deviation (≥0.05 mV)  on ECG at presentation
- ≥2 anginal events in prior 24 h
- Prior use of aspirin within 7 days
- Elevated serum troponin I or CK-MB• Chronic active liver or muscle diseases
• White blood cell counts <4 × 109/L or platelet counts <100 × 109/L
• Renal failure with creatinine >265.2 mol/L (3 mg/dL) or creati-
nine clearance <0.501 mL/s (30 mL/min)
3 Cardio
•
•
•
•
•
•
•
•
•
•
•
P
t
•
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[42 Y. Jang et al. / Journal of 
Left ventricular ejection fraction (LVEF) <30% at screening visit
Previously or currently treated with atorvastatin or other statins
History of intolerance or hypersensitivity to atorvastatin or other
statins
Medications that have a potential for drug–drug interactions, e.g.
ﬁbric acid derivatives, cyclosporin, macrolide antibiotics, pro-
tease inhibitors, azole antifungals, niacin, ezetimibe, verapamil
Glycoprotein IIb/IIIa inhibitors as required medication
Patients whose treatment with beta-blockers, angiotensin-
converting enzyme (ACE) inhibitors, calcium channel antago-
nists, or angiotensin receptor blockers (ARB) had not remained
stable within 1 month of study enrollment
Medications that were contraindicated in the presence of co-
administration with clopidogrel, aspirin, and heparin
Participation in any other studies involving investigational or
marketed products within 1 month prior to entry in the study
Any condition rendering the patient unable to understand the
nature or scope of the study and/or rendering the patient to be
unable or unlikely to follow the protocol
History of known alcohol or drug abuse within the last 12 months
Any condition that might increase the risk to the patient for any
adverse event (AE) or abnormal laboratory ﬁnding
rohibited medications
The following medications were prohibited for the duration of
he study:
All HMG-CoA reductase inhibitors and antilipidemic medications
including niacin, bile acid sequestrants, cholesterol absorption
inhibitors (e.g. ezetimibe), cytochrome P450 inhibitors (including
grapefruit juice >1.2 L/day), macrolide antibiotics, azole anti-
fungals, protease inhibitors, immunosuppressive medications
(i.e. cyclosporin), psyllium (>2 tablespoons/day), verapamil, and
ﬁsh oil
eferences
[1] Patti G, Chello M,  Candura D, Pasceri V, D’Ambrosio A, Covino E,
Di  Sciascio G. Randomized trial of atorvastatin for reduction of postopera-
tive atrial ﬁbrillation in patients undergoing cardiac surgery: results of the
ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After car-
diac surgery) study. Circulation 2006;114:1455–61.
[2] Patti G, Chello M,  Pasceri V, Colonna D, Nusca A, Miglionico M,
D’Ambrosio A, Covino E, Di Sciascio G. Protection from procedural myocardial
injury by atorvastatin is associated with lower levels of adhesion molecules
after percutaneous coronary intervention: results from the ARMYDA-CAMs
(Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell
Adhesion Molecules) substudy. J Am Coll Cardiol 2006;48:1560–6.
[3] Patti G, Pasceri V, Colonna G, Miglionico M,  Fischetti D, Sardella G,
Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in
patients with acute coronary syndromes undergoing early percutaneous coro-
nary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll
Cardiol 2007;49:1272–8.
[4] Patti G, Nusca A, Chello M,  Pasceri V, D’Ambrosio A, Vetrovec GW,
Di  Sciascio G. Usefulness of statin pretreatment to prevent contrast-induced
nephropathy and to improve long-term outcome in patients undergoing per-
cutaneous coronary intervention. Am J Cardiol 2008;101:279–85.
[5] Patti G, Nusca A, Mangiacapra F, Gatto L, D’Ambrosio A, Di Sciascio G. Point-
of-care measurement of clopidogrel responsiveness predicts clinical outcome
in  patients undergoing percutaneous coronary intervention results of the
ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage dur-
ing Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol
2008;52:1128–33.
[6] Hao PP, Chen YG, Wang JL, Ji WQ,  Xue L, Liu XH, Wang XL, Zhang Y. Meta-analysis
of the role of high-dose statins administered prior to percutaneous coronary
intervention in reducing major adverse cardiac events in patients with coronary
artery disease. Clin Exp Pharmacol Physiol 2010;37:496–500.[7] Zhang F, Dong L, Ge J. Effect of statins pretreatment on periprocedural myocar-
dial  infarction in patients undergoing percutaneous coronary intervention: a
meta-analysis. Ann Med  2010;42:171–7.
[8] Winchester DE, Wen  X, Xie L, Bavry AA. Evidence of pre-procedural statin ther-
apy: a meta-analysis of randomized trials. J Am Coll Cardiol 2010;56:1099–109.
[
[logy 63 (2014) 335–343
[9] Merla R, Reddy NK, Wang FW,  Uretsky BF, Barbagelata A, Birnbaum Y.
Meta-analysis of published reports on the effect of statin treatment before per-
cutaneous coronary intervention on periprocedural myonecrosis. Am J Cardiol
2007;100:770–6.
10] Mood GR, Bavry AA, Roukoz H, Bhatt DL. Meta-analysis of the role of statin
therapy in reducing myocardial infarction following elective percutaneous
coronary intervention. Am J Cardiol 2007;100:919–23.
11] Ebrahimi R, Saleh J, Toggart E, Shah AP, Azmoon S, Babaei H, Lee J,
Smith R, Movahed MR,  Rubin SA. Effect of preprocedural statin use on proce-
dural myocardial infarction and major cardiac adverse events in percutaneous
coronary intervention: a meta-analysis. J Invasive Cardiol 2008;20:292–5.
12] Yun KH, Jeong MH,  Oh SK, Rhee SJ, Park EM,  Lee EM,  Yoo NJ, Kim NH,
Ahn YK, Jeong JW.  The beneﬁcial effect of high loading dose of rosuvastatin
before percutaneous coronary intervention in patients with acute coronary
syndrome. Int J Cardiol 2009;137:246–51.
13] Sun Y, Qi G, Gao Y, Zhang H, Pang X, Zhao W,  Zhang Z. Effect of different loading
doses of atorvastatin on percutaneous coronary intervention for acute coronary
syndromes. Can J Cardiol 2010;26:481–5.
14] Yun KH, Oh SK, Rhee SJ, Yoo NJ, Kim NH, Jeong JW.  12-Month follow-up results
of  high dose rosuvastatin loading before percutaneous coronary intervention
in  patients with acute coronary syndrome. Int J Cardiol 2011;146:68–72.
15] Tsunoda R, Sakamoto T, Kojima S, Ogata Y, Kitagwa A, Ogawa H.  Recurrence of
angina pectoris after percutaneous coronary intervention is reduced by statins
in  Japanese patients. J Cardiol 2011;58:208–15.
16] Yun KH, Shin SN, Ko JS, Rhee SJ, Kim NH, Oh SK, Jeong JW.  Rosuvastatin-induced
high-density lipoprotein changes in patients who  underwent percutaneous
coronary intervention for non-ST-segment elevation acute coronary syndrome.
J  Cardiol 2012;60:383–8.
17] Ge J, Kim YJ, Jang YS, Zhu J, Marschner IC, Lam W.  Design and rationale of a
study in Asia of atorvastatin pretreatment in patients undergoing percutaneous
coronary intervention for non-ST elevation acute coronary syndromes. J Cardiol
2010;55:303–8.
18] Anderson JL, Adams CD, Antman EM,  Bridges CR, Califf RM, Casey Jr DE, Chavey
2nd  WE,  Fesmire FM,  Hochman JS, Levin TN, Lincoff AM,  Peterson ED, Theroux
P, Wenger NK, Wright RS, et al. ACC/AHA 2007 guidelines for the manage-
ment of patients with unstable angina/non ST-elevation myocardial infarction.
Circulation 2007;116:e148–304.
19] Thygesen K, Alpert JS, White HD. Universal deﬁnition of myocardial infarction.
Eur Heart J 2007;28:2525–38.
20] Veselka J, Zemanek D, Hajek P, Maly M, Adlova R, Martinkovicova L, Tesar D.
Effect of two-day atorvastatin pretreatment on the incidence of periprocedural
myocardial infarction following elective percutaneous coronary interven-
tion: a single-center, prospective, and randomized study. Am J Cardiol
2009;104:630–3.
21] Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R,
Joyal SV, Hill KA, Pfeffer MA,  Skene AM,  Pravastatin or Atorvastatin Evaluation
and Infection Therapy – Thrombolysis in Myocardial Infarction 22 Investiga-
tors. Intensive versus moderate lipid lowering with statins after acute coronary
syndromes. N Engl J Med 2004;350:1495–504.
22] Gibson CM,  Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP. Effect of
intensive statin therapy on clinical outcomes among patients undergoing per-
cutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A
PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Ther-
apy – Thrombolysis in Myocardial Infarction 22) Substudy. J Am Coll Cardiol
2009;54:2290–5.
23] Schwartz GG, Olsson AG, Ezekowitz MD,  Ganz P, Oliver MF,  Waters D,
Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with
Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of ator-
vastatin on early recurrent ischemic events in acute coronary syndromes: the
MIRACL study: a randomized controlled trial. JAMA 2001;285:1711–8.
24] Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, Colombo A,
Yun KH, Jeong MH,  Kim JS, Choi D, Bozbas H, Kinoshita M,  Fukuda K,  Jia XW,
et  al. Clinical beneﬁt of statin pretreatment in patients undergoing percuta-
neous coronary intervention: a collaborative patient-level meta-analysis of 13
randomized studies. Circulation 2011;123:1622–32.
25] Ko DT, Wijeysundera HC, Yun L, Austin PC, Cantor WJ,  Tu JV. Effectiveness of
preprocedural statin therapy on clinical outcomes for patients with stable coro-
nary artery disease after percutaneous coronary interventions. Circ Cardiovasc
Qual Outcomes 2011;4:459–66.
26] Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Cham-
bers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L,
Mehran R, Moussa ID, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous
Coronary Intervention: A Report of the American College of Cardiology Foun-
dation/American Heart Association Task Force on Practice Guidelines and
the  Society for Cardiovascular Angiography and Interventions. Circulation
2011;124:e574–651.
27] European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z,
Catapano AL, De Backer G, Graham I, Taskinen MR,  Wiklund O, Agewall S, Alegria
E,  Chapman MJ,  Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, et al.
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for
the management of dyslipidaemias of the European Society of Cardiology (ESC)
and  the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769–818.
28] Grines CL, Dixon S. A nail in the cofﬁn of troponin measurements after percu-
taneous coronary intervention. J Am Coll Cardiol 2011;57:662–3.
29] Lim CC, van Gaal WJ,  Testa L, Cuculi F, Arnold JR, Karamitsos T, Francis JM,
Petersen SE, Digby JE, Westaby S, Antoniades C, Kharbanda RK, Burrell LM,
ardio
[
[
[
[
[Y. Jang et al. / Journal of C
Neubauer S, Banning AP. With the universal deﬁnition, measurement of cre-
atine kinase-myocardial band rather than troponin allows more accurate
diagnosis of periprocedural necrosis and infarction after coronary intervention.
J  Am Coll Cardiol 2011;57:653–61.
30] Thygesen K, Alpert JS, Jaffe AS, Simoons ML,  Chaitman BR, White HD. Third
universal deﬁnition of myocardial infarction. Circulation 2012;126:2020–35.
31] LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM,
Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT)
Investigators. Intensive lipid lowering with atorvastatin in patients with stable
coronary disease. N Engl J Med  2005;352:1425–35.
32] Kurogi K, Sugiyama S, Sakamoto K, Tayama S, Nakamura S, Biwa T,
Matsui K, Ogawa H, COMPACT-CAD Investigators. Comparison of pitavastatin
[logy 63 (2014) 335–343 343
with atorvastatin in increasing HDL-cholesterol and adiponectin in patients
with dyslipidemia and coronary artery disease: the COMPACT-CAD study. J
Cardiol 2013;62:87–94.
33] Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group. Efﬁcacy of ator-
vastatin in primary hypercholesterolemia. Am J Cardiol 1997;79:1248–52.
34] Wang KY, Ting CT. A randomized, double-blind, placebo-controlled, 8-week
study to evaluate the efﬁcacy and safety of once daily atorvastatin (10 mg)  in
patients with elevated LDL-cholesterol. Jpn Heart J 2001;42:725–38.
35] Wu CC, Sy R, Tanphaichitr V, Hin AT, Suyono S, Lee YT. Comparing the efﬁcacy
and safety of atorvastatin and simvastatin in Asians with elevated low-density
lipoprotein-cholesterol—a multinational, multicenter, double-blind study. J
Formos Med  Assoc 2002;101:478–87.
